GlaxoSmithKline Receives Approvable Letter For New Indications For ARIXTRA(R) (Fondaparinux Sodium) Injection

... GlaxoSmithKline (GSK) announced today that the U.S. Food and Drug Administration (FDA) has issued an approvable letter for the once-daily anticoagulant, ARIXTRA (fondaparinux sodium) Injection, for the treatment of patients with -- Unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) -- ST-segment elevation myocardial infarction (STEMI). [click link for full article] ...